gbfi

Recent ReaScan CXCL13 publication:

CXCL13 in laboratory diagnosis of Lyme neuroborreliosis - the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples

Earlier this month, an article showing performance evaluation results of Reagena’s ReaScan CXCL13 and Luminex-based recomBead was published in the peer-reviewed European Journal of Clinical Microbiology & Infectious Diseases. In the study, a total of 209 CSF samples from definite LNB, probable early LNB and non-LNB patients were analyzed.

The results demonstrated that the recomBead and the ReaScan CXCL13 assays show comparable performance in the identification of LNB. In addition, it was highlighted that the ReaScan CXCL13 is easy to use and it has short turnaround time with possibility to analyze one sample at a time.

Ref.: Haglund S et al. CXCL13 in laboratory diagnosis of Lyme neuroborreliosis - the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples. Eur J Clin Microbiol Infect Dis. 2021 Oct 9. doi: 10.1007/s10096-021-04350-y.

See also the previous peer-reviewed ReaScan CXCL13 publications showing results of our CXCL13 rapid test against the commercial CXCL13 ELISA methods:

  •  Pietikäinen A et al. Point-of-care testing for CXCL13 in Lyme neuroborreliosis. Diagn Microbiol Infect Dis. 2018 Jul;91(3):226-228. doi: 10.1016/j.diagmicrobio.2018.02.013.

  •  Ziegler K et al. Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis. J Clin Microbiol. 2020 Aug 24;58(9):e00207-20. doi: 10.1128/JCM.00207-20.